Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HypoFocal SRT: Focal Salvage Radiotherapy and ADT for Recurrent Prostate Cancer
NCT05746806Phase 2Active, not recruiting
- Sponsor
- Insel Gruppe
- Start
- Mar 2023
- Primary completion
- Nov 2027
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of triptorelin in prostate cancer (PCa), sponsored by Insel Gruppe. Primary endpoint: Biochemical Relapse-Free Survival at 2 years. Started Mar 2023; status: active, not recruiting.
02
Drugs
triptorelin
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT05746806.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05746806.